The Cutting Edge of Cancer Innovation
Oncolytics is a biotechnology company developing REOLYSIN®, an immuno-oncology viral-agent, as a potential treatment for a variety of tumor types. The Company is listed on the Toronto Stock Exchange (TSX:ONC) and quoted on the OTCQX® Best Market (OTCQX:ONCYF). In addition to the information available on this site, investors can access the Company’s regulatory filings on the SEDAR website at www.sedar.com and on the EDGAR website at www.sec.gov.
Financials
Access our quarterly and year-end financial statements, MD&A, information circulars and annual reports.
Corporate Governance
Oncolytics Biotech Inc. believes in a transparent and forward-facing approach to business.
Letter to Stakeholders
Q1 Letter to ShareholdersAnalyst Coverage
Read MoreOncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas Read More
Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer Read More
Exploring REOLYSIN®’s Objective Response Rate in Females with Colorectal Cancer Read More
